Interesting, William.
I am also concerned with lowering E's too far status post
AAS, thereby unnecessarily extending the period of plaque deposition within the cardiovascular system.
The idea of employing AI's during PCT is certainly not a new one. But the idea that a more expensive and hard-to-obtain type of same is preferable completely unwarranted by the arguemetns provided in this paper.
I certainly would recommend all users of
testosterone during
AAS use maintain somewhat normal estrogen levels DURING the cycle, as this, by my experience, helps in restoring the system following the cycle.
And this leads to the best reason to NOT use an AI (once
testosterone conversion has subsided to the point E's are no longer elevated), or
finasteride, or any of the other nonsensical ideas this Robert's character has come up with: the underlying goal during PCT is to normalize the metabolic pathways. Employing powerful endocrine disrupters is contraindicated to that end.